Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2

被引：18

作者：

Bartels, S. ^{[1
]}

Faisal, M. ^{[1
]}

Buesche, G. ^{[1
]}

Schlue, J. ^{[1
]}

Kreipe, H. ^{[1
]}

Lehmann, U. ^{[1
]}

机构：

[1] Hannover Med Sch, Inst Pathol, Hannover, Germany

来源：

LEUKEMIA | 2018年 / 32卷 / 02期

关键词：

JAK2V617F ALLELE BURDEN; ESSENTIAL THROMBOCYTHEMIA; PRIMARY MYELOFIBROSIS; SRSF2;

D O I：

10.1038/leu.2017.298

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：556 / 558

页数：3

共 13 条

[1] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[2] Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease [J].

Barosi, Giovanni ;

Massa, Margherita ;

Campanelli, Rita ;

Fois, Gabriela ;

Catarsi, Paolo ;

Viarengo, Gianluca ;

Villani, Laura ;

Poletto, Valentina ;

Bosoni, Tiziana ;

Magrini, Umberto ;

Gale, Robert P. ;

Rosti, Vittorio .

LEUKEMIA RESEARCH, 2017, 60 :18-23

[3] SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation [J].

Bartels, S. ;

Lehmann, U. ;

Buesche, G. ;

Schlue, J. ;

Mozer, M. ;

Stadler, J. ;

Triviai, I. ;

Alchalby, H. ;

Kroeger, N. ;

Kreipe, H. .

LEUKEMIA, 2015, 29 (01) :253-255

[4] Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms [J].

Bartels, Stephan ;

Schipper, Elisa ;

Hasemeier, Britta ;

Kreipe, Hans ;

Lehmann, Ulrich .

ONCOTARGET, 2016, 7 (21) :30084-30093

[5]

Bartels S, 2015, METHODS MOL BIOL, V1315, P103, DOI 10.1007/978-1-4939-2715-9_8

[6] Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors [J].

Cerquozzi, S. ;

Tefferi, A. .

BLOOD CANCER JOURNAL, 2015, 5 :e366-e366

[7] Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm [J].

Chen, Peisong ;

Ouyang, Juan ;

Liang, Jianming ;

Yu, Xuegao ;

Huang, Bin .

CLINICAL LABORATORY, 2016, 62 (08) :1477-1481

[8] SRSF2 mutation is present in the hypercellular and prefibrotic stage of primary myelofibrosis [J].

Lehmann, Ulrich ;

Bartels, Stephan ;

Hasemeier, Britta ;

Geffers, Robert ;

Schlue, Jerome ;

Buesche, Guntram ;

Hussein, Kais ;

Kreipe, Hans .

BLOOD, 2013, 121 (19) :4011-4012

[9] Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms [J].

Lundberg, Pontus ;

Karow, Axel ;

Nienhold, Ronny ;

Looser, Renate ;

Hui Hao-Shen ;

Nissen, Ina ;

Girsberger, Sabine ;

Lehmann, Thomas ;

Passweg, Jakob ;

Stern, Martin ;

Beisel, Christian ;

Kralovics, Robert ;

Skoda, Radek C. .

BLOOD, 2014, 123 (14) :2220-2228

[10] Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome [J].

Luque Paz, Damien ;

Chauveau, Aurelie ;

Boyer, Francoise ;

Buors, Caroline ;

Samaison, Laura ;

Cottin, Laurane ;

Seegers, Valerie ;

Ferec, Claude ;

Le Marechal, Cedric ;

Gueguen, Paul ;

Lippert, Eric ;

Ianotto, Jean-Christophe ;

Ugo, Valerie .

GENES CHROMOSOMES & CANCER, 2017, 56 (05) :354-362

← 1 2 →